Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer.

Francisco Robert; Michael Gordon; Lee S. Rosen; David S. Mendelson; Marilyn Mulay; B. J. Adams; Delia Alvarez; Charles P. Theuer; B. R. Leigh

doi:10.1200/jco.2010.28.15_suppl.3038

Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer.

Identifier:nobleid.org/w1/20260515/C27DBDDC

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C27DBDDC.svg?ark=w1%2F20260515%2FC27DBDDC)](https://nobleid.org/work/w1/20260515/C27DBDDC)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer.

Identifier:nobleid.org/w1/20260515/C27DBDDC

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C27DBDDC.svg?ark=w1%2F20260515%2FC27DBDDC)](https://nobleid.org/work/w1/20260515/C27DBDDC)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work